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Abstract
Sjögren’s syndrome is a common autoimmune disease (~0.7% of European Americans) typically
presenting as keratoconjunctivitis sicca and xerostomia. In addition to strong association within
the HLA region at 6p21 (Pmeta=7.65×10−114), we establish associations with IRF5-TNPO3
(Pmeta=2.73×10−19), STAT4 (Pmeta=6.80×10−15), IL12A (Pmeta =1.17×10−10), FAM167A-BLK
(Pmeta=4.97×10−10), DDX6-CXCR5 (Pmeta=1.10×10−8), and TNIP1 (Pmeta=3.30×10−8).
Suggestive associations with Pmeta<5×10−5 were observed with 29 regions including TNFAIP3,
PTTG1, PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2, and PHIP amongst others. These results
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shighlight the importance of genes involved in both innate and adaptive immunity in Sjögren’s
syndrome.
Sjögren’s syndrome is a common (~0.7% of European Americans1), chronic, autoimmune
condition characterized by exocrine gland dysfunction resulting in substantial morbidity.
Females are affected at a rate of approximately 10 times more than males2,3. Although
patients are identified clinically by oral and ocular manifestations, the full disease spectrum
may encompass a complex myriad of systemic features, making diagnosis a significant
clinical challenge4. Current American-European Consensus Group classification criteria
require either the presence of anti-Ro and/or -La autoantibodies or histologic evidence of
inflammation within salivary glands plus other subjective and objective measures of
keratoconjunctivitis sicca and xerostomia5. Therapeutic options are primarily palliative and
do little to prevent irreversible exocrine gland damage6.
Sjögren’s syndrome pathophysiology includes concurrent dysregulation of innate and
adaptive immune pathways involving both cell-mediated and humoral disease processes that
are incompletely understood7. Labial salivary gland and peripheral blood gene expression
microarray studies have demonstrated dysregulation of type I interferon-inducible genes8,9.
Previous work in Sjögren’s syndrome genetics is limited to candidate gene studies, yet
strong association with several human leukocyte antigen (HLA) molecules, including HLA-
DR, HLA-DQB1, and HLA-DQA1, has been established10,11. Several non-HLA regions have
been implicated in the disease, such as IRF5 and STAT412-15; however, none of these
associations have exceeded the genome-wide significant (GWS) threshold of P = 5×10−8
(Supplementary Table 1). In this study, genome-wide association and large-scale replication
approaches were used to identify new risk loci in a case-control cohort of primary Sjögren’s
syndrome patients.
Results
To maximize the power of our study, we formed the Sjögren’s Genetics Network (SGENE),
a collaborative research effort comprising multiple international sites (Supplementary Figure
1 and Supplementary Table 2). Dataset 1 (DS1) included 395 cases and 1975 population
controls of European descent after implementing quality control (QC; see Online Methods
and Supplementary Table 2). Genotyping was performed using the Illumina Omni1-Quad
array. Dataset 2 (DS2) consisted of 1243 cases and 4779 population controls genotyped on
the Illumina ImmunoChip, and Dataset 3 (DS3) included 1158 cases and 3071 population
controls genotyped on a supplemental custom array designed to include variants not present
on the ImmunoChip (all of European descent and after QC; Supplementary Figure 1b).
Dataset 4 (DS4) evaluated 1541 cases and 2634 population controls genotyped on the
Illumina ImmunoChip focusing on variants exclusive to DS4 and not common between DS1
and DS2 (Supplementary Figure 1b). Imputation was performed in regions with P<5×10−5
to increase the number of overlapping variants available for analysis (Supplementary Figure
1c and 1d).
Human Leukocyte Antigen (HLA)
The HLA region at 6p21 was the only association that exceeded the GWS threshold of
P<5×10−8 in DS1 (Supplementary Figure 2). After imputation, we found the peak effect at
rs112357081 near HLA-DRA with PDS1=1.01×10−32 (Table 1; Supplementary Figure 3). No
inflation was observed in the test statistic (λGC=1.0) and no significant deviation from the
expected distribution of P-values was detected after removing the HLA region
(Supplementary Figure 4). After meta-analysis between the imputed DS1 and DS2 (Figures
1 and 2; Supplementary Figure 1), strong association spanned a region that included the
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sHLA Class I, III, and II loci (Figure 2a; Supplementary Table 3), with peak association
observed 5′ of HLA-DQB1 in the HLA Class II region at rs115575857 with
Pmeta=7.65×10−114 (Table 1 and Figure 2a). A second set of variants not in linkage
disequilibrium (LD) with rs115575857 was also identified peaking at rs116232857
(Pmeta=1.33×10−96; Table 1 and Figure 2a).
Further dissection through logistic regression analysis in DS2 adjusting for rs115575857
identified an ~5 Mb haplotype encompassing the extended HLA region (Supplementary
Figure 5). In addition, a narrow region of residual association tagged by rs116232857
(Presidual=7.00×10−26) was observed in the HLA-DRA through HLA-DQA1 regions
(Supplementary Figure 5). Logistic regression adjusting for rs115575857 and rs116232857
accounted for most of the association within the HLA region (the residual association in the
region at rs115146037 went from 10−80 to 10−9; Supplementary Figure 5), thus identifying
the presence of at least two independent effects.
Classical HLA alleles were imputed into our dataset to better understand the relationship
between the HLA region variants tested in this study to those reported previously. The top
associated classical allele was HLA-DQB1*0201 (Pmeta=1.38×10−95) followed closely by
HLA-DQA1*0501 (Pmeta=8.50×10−94; Supplementary Table 4 and Supplementary Figure
6). We used logistic regression adjusting for both the top associated classical HLA alleles
and the variants identified through the meta-analysis of DS1 and DS2. As previously
described16, our data shows that HLA-DQB1*0201, HLA-DQA1*0501, and HLA-
DRB1*0301 are in strong LD (r2>0.97), and adjusted logistic regression using any of the
three accounted for the observed association. Moreover, each of these classical alleles
accounted for the association at rs115575857. Likewise, rs115575857 explained the
association at each of the three classical alleles (Supplementary Figure 6). Adjusting for
rs116232857 could account for the association at HLA-DQB1*0501, a previously reported
protective allele in Sjögren’s syndrome11. However, HLA-DQB1*0501 could not account
for the association observed at rs116232857, suggesting that rs116232857 better tags the
functional effect(s) than the classical allele.
Enrichment analysis using all variants with Pmeta<5×10−5 identified a statistically significant
association of disease-associated variants within 100 bp of regions found to be cross-linked
to the transcription factor (TF) RFX5 (P=1.53×10−14) by ENCODE ChIP-seq studies17. In
total, 161 variants contributed to the enrichment in our dataset with all but one located in the
HLA region. To further evaluate the influence of the extensive LD in the HLA, we tested for
enrichment of Sjögren’s syndrome-associated variants in RFX5 ChIP-seq peaks using only
the HLA region variants present in DS1 as the background and continued to observe
significant enrichment (P=9.24×10−7; Supplementary Table 5).
To evaluate the functional mechanism of this RFX5 enrichment within the HLA the variants
near RFX5 ChIP-seq peaks were tested as expression quantitative trail loci (eQTL), resulting
in several statistically significant results (Figure 3a-e); Supplementary Table 6 and
Supplementary Figure 7). The top overall eQTL was observed with rs114846898 and HLA-
DRB6 (PANOVA=1.03×10−42; Figure 3a). A modest eQTL was observed for rs116232857
and HLA-DRB6 (PANOVA=1.77×10−12); however, we found that rs116232857 and
rs114846898 were nearly in perfect LD with each other (D’=0.98), suggesting that the
association at rs116232857 might be due to rs114846898. Looking at the adjusted analysis
results, we found that rs115575857 and rs116232857 could explain rs114846898, but
adjusting for rs115575857 and rs114846898 left residual association (Presidual=9.44×10−7)
at rs116232857, suggesting that rs116232857 likely tags additional functional variant(s).
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sIn addition to the strong association observed in the HLA region, six non-HLA loci
surpassed the GWS threshold, including IRF5, STAT4, IL12A, BLK, CXCR5 and TNIP1
(Table 2 and Figure 1).
Interferon Regulatory Factor 5 (IRF5)
The most statistically significant association outside the HLA region after meta-analysis was
observed in the region of IRF5. In total, 67 SNPs exceeded the Pmeta=5×10−8 threshold,
with the peak effect observed in the IRF5 promoter region (rs3757387, Pmeta=2.73×10−19;
Figure 2b; Supplementary Table 7 and Supplementary Figure 8). A group of variants, tagged
by rs17339836 (Pmeta=2.43×10−16) and spanning IRF5 and TNPO3, were not correlated
with the promoter variants (Figure 2b).
Logistic regression adjusting for rs3757387 explained all of the promoter region association,
while residual association persisted with variants spanning the IRF5-TNPO3 genes tagged
by rs17339836 (Presidual=2.86×10−4; Supplementary Figure 9). Moreover, a group of
variants tagged by rs6948875 that were not associated in the unadjusted single marker
analysis became statistically significant when adjusting for rs3757387. Adjusting for both
rs3757387 and rs17339836 again resulted in residual association of the region tagged by
rs6948875 and rs10954213 (Supplementary Figure 9). Since rs10954213 was statistically
significant in the single marker analysis (Supplementary Table 7), this SNP was added to the
model in lieu of rs6948875. Logistic regression models adjusting for rs3757387,
rs17339836, and rs10954213 resulted in no residual association in the regions, indicating the
likelihood of three independent effects. Bioinformatics database mining of this region
indicated that the associated variants were located within a variety of biologically relevant
features encompassing a wide range of potential functional mechanisms (Supplementary
Figure 10).
Signal Transducer and Activator of Transcription 4 (STAT4)
Statistically significant association exceeding GWS was observed between Sjögren’s
syndrome and 12 variants, 8 of which fall within the third intron of the STAT4 locus, with
peak association at an insertion-deletion (indel) polymorphism (rs10553577;
Pmeta=6.80×10−15; Figure 2c; Supplementary Table 8 and Supplementary Figures 11 and
12). As expected, the indel rs10553577 accounted for the association within the region of
STAT4; however, residual association was observed with rs3024918 (Presidual=2.70×10−4) in
the promoter region of STAT1, but did not surpass our required threshold (P<1×10−4) after
adjustment for an independent effect (Supplementary Figure 12). Bioinformatics databases
revealed a large number of TFs bound to both regions (Supplementary Figure 13); however,
neither effect resulted in a statistically significant eQTL (data not shown).
Interleukin 12A (IL12A)
Seven variants spanning the entire region from the promoter demonstrated strong
association, with peak association occurring 5.3kb 3′ of IL12A at rs485497
(Pmeta=1.17×10−10; Figure 2d; Supplementary Table 9 and Supplementary Figure 14).
Logistic regression analysis adjusting for rs485497 indicated this variant accounted for all
the observed association (Supplementary Figure 15). To determine the functional role of the
variants associated between IL12A and Sjögren’s syndrome, eQTL analysis was done for all
variants showing evidence of association in the region. Of the variants exceeding GWS, only
rs485497 was associated with IL12A transcript expression; however, seven variants 3′ of
IL12A influenced expression more significantly, with the eQTL peaking at rs4680536
(Figure 3f; Supplementary Table 6). Haplotype analysis of the IL12A associated variants
indicates the presence of only one risk haplotype and the possibility that rs485497 may tag
functional variants located on either side of this SNP (Supplementary Figure 15), which is
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ssupported by the presence of multiple transcription factors and other regulatory elements
located in the flanking LD blocks (Supplementary Figure 16).
B Lymphoid Kinase (BLK)
A total of 30 variants on chromosome 8 exceeded GWS in the region of FAM167A and BLK
(Figure 2e; Supplementary Table 10 and Supplementary Figure 17). Maximum association
after meta-analysis was observed in the shared promoter region of FAM167A-BLK at
rs2736345 (Pmeta=4.97×10−10); however, this SNP was not statistically significant in DS1
(Table 2). The second most significant variant after meta-analysis (significant in both DS1
and DS2) was rs2729935 with Pmeta=6.85×10−10, which is located in the first intron of
BLK. Logistic regression analysis adjusting for rs2729935 (as this variant was significant in
both datasets) indicated residual association (Presidual=1.75×10−3) present at rs2736345.
However, adjusting for rs2736345 in the logistic model showed the likely presence of only
one effect accounting for all the association in the region (Supplementary Figure 18).
Using expression data for BLK, eQTL analysis of the associated variants revealed several
with the potential to influence transcript expression, including the top overall SNP in the
region of BLK, rs2736345 (Supplementary Table 6). The most statistically significant eQTL
was located in the first intron of BLK at rs2409781 (Figure 3g), a variant loosely correlated
with rs2736345 and rs2729935 (r2≈0.5). Evaluation of FAM167A probes with the variants
associated with Sjögren’s syndrome yielded greater statistical significance than those with
BLK (Figure 3h). Bioinformatics analysis indicated the presence of many transcriptionally
relevant markers not only in the shared promoter region, but also in the first intron of BLK,
suggesting the possibility that association in this region impacts the transcriptional
regulation of BLK and/or FAM167A (Supplementary Figure 19).
Chemokine (C-X-C motif) receptor 5 (CXCR5)
Association with a variant ~16 kb 5′ of the coding region of CXCR5 was observed at
rs7119038 (Pmeta=1.10×10−8; Figure 2f; Supplementary Table 11 and Supplementary Figure
20). Three additional variants also exceeded the GWS threshold extending to rs11217033
located as far as ~90 kb 5′ of CXCR5 and as close to ~12 kb 5′ of the neighboring gene,
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (DDX6) (Figure 2f). Adjusting for rs7119038
explained all the association signals in this region (Supplementary Figure 21). Although no
statistically significant eQTLs were present in the region for CXCR5, bioinformatics
analysis indicated the presence of many regulatory elements throughout the region
(Supplementary Figure 22). Assessment of eQTLs for DDX6 was not possible as the probe
failed QC in the gene expression study.
TNFAIP3 interaction protein 1 (TNIP1)
In the region of TNIP1, one SNP, rs6579837, exceeded GWS with Pmeta=3.30×10−8;
however, 29 additional variants showed evidence of association with Pmeta<5×10−5 (Figure
2g; Supplementary Table 12 and Supplementary Figure 23). Logistic regression analysis
adjusting for rs6579837 accounted for all association observed in the region (Supplementary
Figure 24). Several of the variants associated with Sjögren’s syndrome were also eQTLs for
the TNIP1 probe, including rs6579837 (Supplementary Table 6). However, the most
statistically significant eQTL was observed at rs73272842 located in TNIP1, where multiple
regulatory elements have been identified (Figure 3i; Supplementary Figure 25).
Suggestive associations with Sjögren’s syndrome
We identified 8 loci that were significant in meta-analysis (Pmeta<5×10−5) but did not
surpass the overall GWS threshold (Supplementary Figure 1b and Table 3). Twenty-one
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sadditional regions surpassed suggestive thresholds for significance (Pmeta<5×10−5) using
DS4 (evaluated variants were exclusive to DS4; Supplementary Figure 1b; Supplementary
Table 13). Further replication of these regions is needed to determine if they are bona fide
risk loci.
Protein-protein interactions and pathway analysis
To assess the potential effects of associated variants on the underlying biology, we utilized
two bioinformatics tools: the Disease Association Protein-Protein Link Evaluator
(DAPPLE)18 and Genomatix Pathway System (GePS)19. DAPPLE defines genomic regions
in LD with variants achieving GWS and suggestive thresholds to determine any potential
protein-protein interaction (PPI) that could elucidate the underlying biological perturbations
in Sjögren’s syndrome. In assessing the GWS variants outside the HLA region only, we
observed no direct PPI, and while indirect PPI was observed, it was not more likely than
expected by chance (Supplementary Figure 26). However, assessing both GWS and
suggestive variants outside the HLA region, we observed a direct PPI network consisting of
9 proteins with 6 direct interactions (P=0.0007) and mean associated protein direct
connectivity of 1.33 (expected=0.63, P=0.048) in addition to an indirect network that
exhibited a mean associated protein indirect connectivity trending toward significance
(P=0.082) (Supplementary Figures 27 and 28). Pathway analysis in GePS for the 6 GWS
loci outside HLA found enrichment in immune signal transduction pathways (3/269 genes;
P=1.54×10−3) and IL-12 signaling pathways (2/7 genes; P=3.80×10−5), primarily due to the
influence of IL12A and STAT4. Adding the remaining 23 loci demonstrating suggestive
association yielded similar results, with dominance of IL-12- and STAT4-dependent
signaling (P=1.63×10−6). Assessing gene involvement in disease processes using Medical
Subject Headings (MeSH) showed significant enrichment in multiple immunologically-
mediated diseases, including non-Hodgkin lymphoma (16/2910 genes; P=1.7×10−6),
systemic lupus erythematosus (SLE) (12/1691 genes; P=4.74×10−6), Epstein-Barr virus
infections (11/1421 genes; P=6.18×10−6), dry eye syndrome (8/868 genes; P=4.99×10−5),
and Sjögren’s syndrome (6/756 genes; P=1.15×10−3).
Discussion
In this study, associations previously identified in the HLA region with Sjögren’s syndrome
were replicated and represent the strongest genetic risk factors with OR ≈ 3.5. Our results
are consistent with a trans-racial meta-analysis of 23 case-control studies evaluating Class II
loci in Sjögren’s syndrome, which also identified HLA-DQA1*0501, HLA-DQB1*0201,
and HLA-DRB*0301 as disease risk factors11. Associated variants in this study with a
Pmeta<5×10−5 were found to be enriched within 100 bp of RFX5 ChIP-seq peaks identified
by ENCODE17. Mutations in RFX5 can lead to the inability to transcribe Class II HLA
molecules and bare lymphocyte syndrome20. In Sjögren’s syndrome, several risk alleles in
or near the RFX5 ChIP-Seq peaks in the Class II region were eQTLs (Figure 3a-e),
indicating that this TF may play a critical pathogenic role. Moreover, eQTLs were identified
in the Class I region with additional HLA molecules, including HLA-C, HLA-A, HLA-H, and
HLA-G, and previous studies have found that RFX5 regulates the expression of these loci21.
Extensive LD between variants in the HLA region may influence the enrichment analysis
performed in GenomeRunner when using all variants as background; however, we continued
to observe enrichment when focusing only on the HLA region. Although we cannot
completely rule out the influence of LD on these results, the observation that several of these
variants are eQTLs further indicates biological relevance.
Although HLA Class II molecules have classically been implicated in Sjögren’s syndrome
risk, HLA Class I loci have also been reported22. This suggests that risk attributed to the
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sHLA region may involve altered expression of multiple genes residing in this region and
important to the immune system through altered binding of RFX5 to DNA motifs and/or
accessory molecules. However, it is likely that other mechanisms, such as amino-acid
changes similar to those identified by Raychaudhuri et al. in rheumatoid arthritis (RA)23, are
involved in the genetic pathophysiology of this region. Comparing the effect sizes for the
two primary HLA associations with other autoimmune diseases, we find that effect sizes in
Sjögren’s syndrome appear stronger than those in SLE and RA, similar to those in MS, and
weaker than those in celiac disease, type I diabetes, and psoriasis (Supplementary Figure
29).
This study also established IRF5-TNPO3, STAT4, IL12A, FAM167A-BLK, DDX6-CXCR5,
and TNIP1 as risk loci. IRF5 is a transcription factor mediating type I interferon responses in
monocytes, dendritic cells, and B cells24 that induces the transcription of interferon-α genes
and the production of pro-inflammatory cytokines (including IL-12, p40, IL-6, and TNF-
α)25 upon viral infection. IRF5 is an established risk locus in SLE, RA, ulcerative colitis,
primary biliary cirrhosis (PBC), and systemic sclerosis (SSc)26-33. In SLE, association with
three independent functional alleles was observed34, similar to the effects described in this
study. Previous studies in Sjögren’s syndrome have also implicated IRF5 as a risk locus, but
only ~15 variants have been tested, with a CGGGG indel polymorphism yielding the most
statistically significant result and appearing to be responsible for the promoter region
association (Supplementary Table 1)13,15,35,36. While we were unable to impute the
CGGGG indel, the variant rs2004640, which is correlated (r2=0.7) with the CGGGG
indel36, demonstrated association (Pmeta=8.86×10−15). Moreover, a three variant haplotype,
consisting of rs3757385, rs2004640, and rs10954213, perfectly tags the CGGGG indel37,38.
Adjusting logistic regression models for these three variants showed significant residual
association (P=1.05×10−7) at rs3757387. After adding rs3757387, residual association
(P=1.64×10−4) was observed at rs17339836, suggesting that adjusting for the 3 SNP
haplotype tagging the CGGGG indel was equivalent to adjusting for only rs10954213.
Additional studies are necessary to determine the precise causal variant in the IRF5
promoter region.
STAT4 is critical for cellular responses initiated by type I interferons and is subsequently
induced by IL-12 in lymphocytes, leading to the transcription of interferon-γ39. The
association of variants in the third intron of STAT4 has been well established in other
inflammatory diseases32,40-42 and has been implicated in Sjögren’s syndrome
(Supplementary Table 1)12,14,15,43. The variants reported in these studies are highly
correlated (r2>0.95) with the associated variant rs10553577 identified in this study.
IL12A encodes the p35 subunit that forms the IL-12 heterodimer with the p40 subunit
encoded by IL12B44. IL-12, an immunomodulatory cytokine primarily secreted by
monocytes and dendritic cells, plays a critical role in T-helper 1 cell differentiation and the
production of interferon-γ by T cells and NK cells45. Although no studies in Sjögren’s
syndrome report association to the IL12A region, several studies in related conditions have
identified variants near IL12A that increase disease risk. Association of variants in the 3′ end
of IL12A have been reported for PBC, while 5′ effects have been described for celiac
disease46-48. Interestingly, the variants reported in PBC showed weak correlations (r2<0.35)
with the top SNP in Sjögren’s syndrome, and analyses adjusting for variants identified in
related diseases continued to exhibit residual association (Presidual<0.05) at rs485497.
Moreover, rs574808, rs495499, and rs6441286, the most statistically significant variants in
PBC42,46, are highly correlated with the eQTL polymorphism reported in this study.
Previous studies observed only suggestive association with the block encompassing the
coding region of this gene, which includes the top overall associated variant, rs485497, in
Lessard et al. Page 8
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sthis study. Thus, the effect in the region of IL12A in Sjögren’s syndrome appears to be at
least partially distinct from PBC.
IRF5, IL12A, and STAT4, all participate in type I interferon pathway signaling. A role for
type I interferon pathway dysregulation in Sjögren’s syndrome has been described through
mRNA gene expression microarray studies of labial salivary glands and peripheral
blood8,9,49,50. Moreover, Emamian et al. has shown that overexpression of type I interferon
inducible genes correlates with titers of the classic Sjögren’s syndrome autoantibodies anti-
Ro and anti-La9. Genetic effects in Sjögren’s syndrome potentially influence both subunits
of IL-12. IRF5 can initiate transcription of IL12B while variants in the region of IL12A have
also been identified as risk factors in this study. Once secreted from dendritic or NK cells,
IL-12 binds T cell receptors, thereby initiating a signaling cascade through STAT4
phosphorylation44.
BLK is a non-receptor src family tyrosine kinase involved in B cell receptor signaling and B
cell development. B cell receptor signaling is essential for proper immune function, deletion
of autoreactive B cells, and subsequent receptor editing51,52. Variants in the BLK locus have
been reported to influence both FAM167A and BLK mRNA and protein expression and are
associated with related diseases, such as SLE53,54. Previous studies have implicated this
region in Sjögren’s syndrome risk with peak association observed within FAM167A at
rs1254979614, while the current study identifies the shared promoter region and the first
intron of BLK as the most statistically significant associations (Figure 2e).
CXCR5, a membrane-bound protein present on some memory B cells and on follicular
helper T cells, acts as a receptor for B-lymphocyte chemoattractant (BLC). Variants in the
region of CXCR5 have been associated with multiple sclerosis and PBC42,55. Although no
genetic associations between Sjögren’s syndrome and CXCR5 have been reported, several
studies have found CXCR5 to be dysregulated in B cells in salivary gland tissues and the
periphery49,56. Interestingly, IL-12 alone can induce CXCR5 expression, leading to the early
commitment of naïve CD4+ T cells to the T follicular helper cell lineage57.
Although the exact function of TNIP1 has not been defined, TNIP1 does bind TNFAIP3,
which suppresses TLR-induced apoptosis by negatively regulating NF-κB58. Variants in the
region of TNIP1 have been found to increase risk for RA, SLE, psoriasis, and SSc59-63. In
SLE, two independent risk haplotypes have been identified, with the H2 haplotype defined
by Adrianto et al.62 corresponding to the association identified in this study. Similar to the
findings reported above, the H2 haplotype in SLE also shows allele-specific differential
expression62.
Considered jointly in the logistic regression model, the genome-wide and suggestively
associated variants could explain a significant proportion of the heritable risk (C statistic =
0.811, Supplementary Table 14). This value is higher than that of the SLE model in women
of European ancestry (C statistic = 0.67)33. Consideration was also given to the effect size of
Sjögren’s syndrome-associated variants in LD with previously established loci achieving
GWS in other autoimmune diseases. Of note, the OR and 95% CI for Sjögren’s syndrome
variants outside the HLA region (Supplementary Table 15 and Supplementary Figure 30)
are comparable to those in related autoimmune diseases, particularly with respect to SLE,
with much greater variability in effect size and CI when considering the variants in the HLA
region (Supplementary Table 16 and Supplementary Figure 29).
Using bioinformatics tools, the combination of GWS and suggestively associated variants
provides some evidence of significant direct and indirect PPI and enrichment of genes
involved in immune signaling processes, particularly with respect to IL-12 and STAT4 and
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smany autoimmune-related diseases. The importance of type I interferons has been
previously recognized in the pathogenesis of Sjögren’s syndrome. However, the type II
interferon pathway, acting through interferon-γ downstream of IL-12 and STAT4, is now
clearly implicated by this study. In addition, multiple genes in the NF-κB pathway,
including TNIP1 and TNFAIP3, support a role for this pathway in Sjögren’s syndrome
pathogenesis. Furthermore, establishing association of several genes important in the
adaptive immune response, including CXCR5 and BLK, as well as suggestive associations in
loci such as FCGR2A, provides insight into the complex genetic architecture for Sjögren’s
syndrome and will facilitate further studies to understand the precise functional
consequences of these risk variants. Taken together, this work provides significant progress
towards explaining the underlying genetic pathophysiology of Sjögren’s syndrome, which
will ultimately provide important new therapeutic targets and potential diagnostic markers,
both of which are lacking.
In summary, we performed a large-scale genetic study in Sjögren’s syndrome and
established IRF5-TNPO3, STAT4, IL12A, FAM167A-BLK, DDX6-CXCR5, and TNIP1 as
risk loci. We have determined that there are likely multiple independent effects within the
HLA and IRF5 regions. Our results also strongly implicate 29 suggestive regions in
Sjögren’s syndrome etiology warranting further study. Together, these results highlight the
importance of the innate and adaptive immune systems in Sjögren’s syndrome etiology.
Future work is needed to replicate these additional candidate associations and to characterize
the causal variant(s) for the regions established in this study.
Online Methods
Subjects
The samples used in this study were collected through the Sjögren’s Genetics Network
(SGENE) and organized at the Oklahoma Medical Research Foundation (OMRF;
Supplementary Table 2). In Dataset 1, 438 Sjögren’s syndrome cases and 3917 population
controls of European descent were subjected to quality control measures outlined below.
Each Sjögren’s syndrome case was genetically matched to five population controls in DS1
using the identity-by-state (IBS) to assess allele sharing as implemented in PLINK64, and
the remaining controls were used in DS2 and DS3. In the next phase, 1521 Sjögren’s
syndrome cases and 6626 population controls were evaluated in DS2 only for variants that
overlapped with DS1; 1169 Sjögren’s syndrome cases and 3078 population controls were
evaluated in DS3; and 1897 cases and 3039 population controls were evaluated in DS4 (313
cases overlapped with DS1). Cases fulfilled the American-European Consensus Group
(AECG) criteria for primary Sjögren’s syndrome5, and all population controls were
evaluated within their respective study. All cases were evaluated by expert clinicians for
possible overlap of clinical features or concurrent diagnosis with other autoimmune
diseases. Written informed consent was obtained by each participant following protocols
approved by the Institutional Review Boards of each institution where the samples were
collected.
Genotyping and Quality Control
Genotypes for DS1 were obtained using the Illumina Omni1-Quad array using Infinium
chemistry at OMRF following the manufacturer’s protocol (Illumina, Inc., San Diego, CA).
Similarly, DS2/DS4 genotyping was performed with the ImmunoChip (an Illumina iSelect
custom array designed by the ImmunoChip Consortium)65. DS3 was genotyped on iSelect
arrays containing 1536 variants overlapped with DS1 that were not available on the
ImmunoChip. Strict quality control procedures were implemented before SNPs were used in
this analysis, including requirements for: well-defined cluster scatter plots; minor allele
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sfrequency >1%; SNP call rate >95%; sample call rate >95%; Hardy-Weinberg proportion
(HWP) test with a P > 0.001 in controls; and P > 0.001 for differential missingness between
cases and controls.
Samples with <95% call rate and excessive increased heterozygosity (>5 standard deviations
from the mean) were excluded from the analysis. Relatedness within the remaining samples
was determined using identity-by-descent (IBD) estimates as determined by PLINK v1.0764.
One individual from each pair was removed if the proportion of the alleles shared identity by
descent was >0.4, with preference towards cases and/or the individual with the highest call
rate. Gender was estimated genetically, and discrepancies with self-report were scrutinized.
Males were required to be heterozygous at rs2557523 (since the G allele for this SNP is only
observed on the Y chromosome and the A allele appears only on the X chromosome) and to
have chromosome X heterozygosity ≤10%, while females were required to be homozygous
for the A allele at rs2557523 and have chromosome X heterozygosity >10%. After quality
control, 648,937 SNPs were available to test for association across all datasets for DS1.
Only SNPs present on both DS1 and DS2 arrays (20,055 after quality control) were used for
meta-analysis and fine-mapping (after imputation, see below for more details). All base pair
positions are given according to the hg19 version of the human genome reference sequence.
Ascertainment of Population Stratification
Genetic outliers were removed from further analysis as determined by principal components
analysis (Supplementary Figure 31)66,67. Population substructure was identified within the
sample set using EIGENSTRAT66 with 40,073 (DS1) and 2,827 (DS2/DS4) independent
markers (r2<0.20 between variants). The resulting Eigenvectors were able to distinguish the
four continental ancestral populations in the following HapMap samples: Africans (ASW,
LWK, MKK, and YRI), Europeans (CEU and TSI), Hispanic and East Indians (MEX and
GIH), and Asians (CHB, CHD, and JPT); Supplementary Figure 30)67,68. We utilized
principal components to identify samples output by EIGENSTRAT that were not of
European ancestry. Samples >6 standard deviations from the mean were eliminated from
further analysis. Samples were then plotted by PC1 and PC2 for only the cases and controls
used in DS1, DS2, or DS4 (Supplementary Figure 31). We further scrutinized and removed
outliers that resided outside the main cluster of cases and controls. In addition, each
Sjögren’s syndrome case was genetically matched to 5 out-of-study population controls for
DS1 using the cluster feature in PLINK v1.0764. After quality control, 395 Sjögren’s
syndrome cases and 1975 population controls in DS1, 1243 cases and 4779 controls in DS2,
1158 cases and 3071 controls on DS3, and 1541 case and 2634 controls in DS4 were
available to test for association (Supplementary Figure 1 and Supplementary Table 2).
Statistical Analysis
To test for SNP-Sjögren’s syndrome association, logistic regression models were computed
as implemented in PLINK v1.0764. The additive genetic model was calculated for
chromosomes 1-22 while adjusting for the first three principal components (as these
accounted for >80% of the variation in the dataset after quality control) and gender. For
chromosome X, only females were tested for association with Sjögren’s syndrome. Meta-
analysis of the SNPs observed in both DS1 and DS2 or DS3 were calculated using a
weighted Z-score in METAL69. Each dataset group was weighted by the square root of its
sample size to control for differences between the two phases. For a locus to be considered it
must have been significant in both datasets and the Pmeta must have exceeded the suggestive
threshold of Pmeta<5×10−5.
To test for meta-analysis heterogeneity, we utilized both the Cochran’s Q test statistic70 and
I2 index71 (reported in the Supplementary Tables 3, 7-12). A P < 0.05 was considered
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ssignificant evidence of heterogeneity for Cochran’s Q test. The I2 index ranges between 0%
and 100%, where I2 equal 0% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%,
indicating low, moderate, high, and very high heterogeneity, respectively. These data are
provided in the Supplementary Tables for each region (Supplementary Tables 3, 7-12).
Linkage disequilibrium and probable haplotypes were determined using HAPLOVIEW ver.
4.272. Haplotype blocks were calculated using the solid-spine of LD algorithms with
minimum r2 values of 0.872. To determine the number of independent effects in each region,
we used step-wise logistic regression adjusting for the most significant variant with
P<0.0001 in the both the adjusted and unadjusted analysis to be considered. Adjusted
logistic regression analysis results for each Sjögren’s syndrome-associated region were
plotted using LocusZoom73.
We computed the C statistic of the multiple logistic regression model using “rms” package
in R. The C statistic is the area under the receiver operator characteristic (ROC) curve that
provides a measure on how well the model can discriminate between cases and population
controls.
Imputation
To increase informativeness, imputation was conducted in subjects from both the DS1 and
DS2 over a 100 kb interval spanning loci that met criteria for genome-wide significance or
select loci demonstrating suggestive significance. Imputation of both datasets was performed
across 12 regions: FCGR2A (chr1: 161,425,205-161,539,360), STAT4 (chr2:
191,844,302-192,066,322), IL12A (chr3: 159,356,623-159,763,806), DGKQ (chr4:
923,459-1,001,272), TNIP1 (chr5: 150,359,504-150,517,221), PTTG1 (chr5:
159,528,253-159,902,455), HLA (chr6: 28,400,000-33,400,000), TNFAIP3 (chr6:
137,938,325-138,254,451), IRF5 (chr7: 128.527,994-128,740,088), BLK (chr8:
11,251,521-11,472,108), PRDM1 (chr6: 106,484,195-106607,814), and DDX6-CXCR5
(chr11: 118,548,473-118,816,980). Imputation was performed using IMPUTE2 and the
European Impute2 1000 Genomes Phase 1 April 2012 reference panel74-76. Imputed
genotypes had to meet or exceed a probability threshold of 0.9, an information measure of
>0.5, and the quality control criteria described above to be included in the analyses.
The HLA classical allele imputation was performed using HLA Genotype Imputation with
Attribute Bagging (HIBAG)77. HIBAG is a highly accurate, computationally tractable
package for imputing HLA types using SNP data without a training dataset in various
populations, including European population. By using HLA SNPs after QC, we imputed the
HLA classical alleles in seven HLA genes in both DS1 and DS2 (Supplementary Figure 6).
Individuals with imputation score < 0.8 and alleles with frequency < 0.01 were removed for
analysis.
Expression Quantitative Trait Loci (eQTL) Analysis
Gene expression profile analysis: We performed global gene expression profiling (GEP)
analysis using peripheral blood on 48,803 probes representing 37,805 loci from the Illumina
HumanWG-6 v3.0 BeadChip in 258 subjects: 182 primary Sjögren’s syndrome cases
meeting AECG 2002 criteria5 and 76 population controls. Analyses were performed in the R
Bioconductor suite. The GEP data were obtained from two separate microarray experiments.
Quality control (QC) was applied in each dataset to filter out transcripts that were expressed
in less than 10% of the subjects (detection call threshold: P<0.05) and probes with
differential missing rates (P<0.001 by Fisher’s exact test) between the two datasets. Re-
annotation and Mapping of Oligonucleotide Array Technologies (ReMOAT) was used to
determine the quality of Illumina BeadArray probes78. Each dataset was then normalized
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sindependently using Robust Multiarray Average (RMA)79 followed by log2 transformation
and quantile normalization. ComBat was subsequently applied to the combined dataset to
adjust for non-biological experimental variation (batch effect)80. After QC and
normalization, 15,063 probes (in 12,248 genes) were kept for further statistical analysis.
Cis-expression quantitative trait loci analysis: Expression levels of the Sjögren’s syndrome-
associated genes identified in the meta-analysis of DS1 and DS2 exceeding GWS were
selected for use as phenotypic traits in cis-eQTL analyses in 222 European subjects (190
cases and 32 controls). Variants associated with Sjögren’s syndrome (P<5×10−5) in the
meta-analysis flanking the target genes were evaluated for genetic association with gene
expression levels using both a linear model in Matrix-eQTL81 (using gender and disease
status as covariates) and Analysis of Variance (ANOVA) models in Prism 6. An eQTL was
considered significant if a false discovery rate (FDR) adjusted P-value, accounting for the
number of tests performed in each region, was P<0.05.
Enrichment analysis
GenomeRunner82 was used to search for statistically significant enrichment of the set of
9,394 SNPs showing suggestive (P<5×10−5) or lower association with Sjögren’s syndrome
with annotated genomic features. Genome annotations include genes and gene prediction
tracks, mRNA and EST tracks, regulation related tracks from ENCODE project, histone
modification marks, comparative genomics tracks, structural variation and repeats tracks.
GenomeRunner evaluates the null hypothesis that co-localization of a set of Sjögren’s
syndrome-associated SNPs with genome annotation features is not statistically significantly
different from what would be observed for a random set of SNPs of the same size. Briefly,
the Sjögren’s syndrome-associated set of SNPs was tested for co-localization with each of
the genome annotation tracks obtained from the UCSC genome database83 for the human
GRCh37/hg19 genome assembly. The whole set of 219,958 SNPs after imputation of select
regions present on the ImmunoChip array was used to randomly select an equally sized
group.
Separate analyses included identification of overrepresented experimentally validated
TFBSs transcription factor binding sites, a total of 148 of them extracted from the
“Transcription Factor ChIP-seq from ENCODE” track (wgEncodeRegTfbsClustered).
Regions of Chromatin State Segmentation by HMM from ENCODE/Broad
(wgEncodeBroadHmmGm12878HMM) were also used to assess overrepresentation of
defined chromatin states containing Sjögren’s syndrome-associated SNPs. Tracks of Histone
Modifications obtained by ChIP-seq from ENCODE/Broad Institute, from ENCODE/
Stanford/Yale/USC/Harvard, and from ENCODE/University of Washington were used for
assessment of epigenetic marks. Unless otherwise noted, data from the GM12878
lymphoblastoid cell line were used, as the majority of the best quality genome annotation
data was obtained from this cell line. The number of Sjögren’s syndrome-associated SNPs
co-localized with a genome annotation track was compared with that of obtained from 1,000
random simulations using Chi-square test. Additional analyses of random sets of SNPs
showed no statistically significant enrichments (data not shown). For an enrichment to be
considered statistically significant, we set a Bonferroni correction threshold for 6000
independent tests at P<8.33×10−6.
RFX5-HLA region enrichment analysis
The HLA region was defined by genomic coordinates chr6:28400295-33398620 (GRCh37/
hg19 human genome assembly). The number of significant SNPs in this region overlapping
with RFX5 binding sites was calculated using BedTools84. The number of all genome-wide
associated SNPs in the HLA region overlapping RFX5 binding sites was calculated and
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scompared with the SNPs significantly associated with Sjögren’s syndrome using Fisher’s
exact test (scipy.stats.fisher_exact function).
Protein-protein interactions
The Disease Association Protein-Protein Link Evaluator (DAPPLE)18 was used to assess the
potential effects of associated variants on the underlying biology. For DAPPLE, seed
variants were converted to genes based on variant overlap and LD structure within the
region of interest. Analyses were performed using the following settings: 10,000
permutations; a common interactor binding degree cutoff of 2; gene regulatory region 50kb
upstream and downstream of transcription start and end; simplification of the indirect
network; and iteration to prioritize genes with a Bonferroni-corrected score of P<0.05. A
total of 14 GWS variants and 114 suggestive variants were present in the DAPPLE
databases; where variants were not found to be present, attempts to find proxies in high LD
were made.
Pathway Analysis in Genomatix
Pathway analysis was carried out using the Genomatix Pathway System (GePS)19. This
system utilizes information obtained from public and proprietary annotation databases to
characterize input gene lists, determine the representation of these genes in canonical
pathways, and create gene networks based on co-citation of genes from the literature. The
public annotation data sets incorporated in this software include gene ontology (GO) and
medical subject headings (MeSH) in addition to others. GePS also provides a probability
statistic using Fisher’s exact test to determine the likelihood of finding the number of co-
represented genes with a particular annotation when considering the length of the input gene
list. Input gene sets were generated using the gene locus nearest the association signals,
which were required to demonstrate suggestive or genome-wide significance, and the
pathway analysis was carried out using the gene symbols of the input set.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Footnotes
Corresponding Author: Kathy L. Moser Sivils Arthritis and Clinical Immunology Research Program Oklahoma
Medical Research Foundation 825 N.E. 13th Street, MS57 Oklahoma City, Oklahoma 73104 sivilsk@omrf.org
Phone: +1 (405) 271-2534 Fax: +1 (405) 271-2578
Author Contributions: C.J.L., K.M.G., J.A.K., C.G.M., J.B.H, and K.L.S. were responsible for the study design.
C.J.L., J.A.I., A.R., K.M.G., C.M.R., S.B., S.L., J.G.B, L.G.G., E.H., J.M.G., D.S.C.G., M.E.G., A.N.M.N.H., K.P.,
J.S.M.M., A.D.F., M.L.E., J.A.L., J.C., R.G., K.S.H., G.D.H., M.T.B., A.J.W.H., P.J.H., D.M.L., L.R., M.D.R.,
D.U.S., T.J.V., P.M.G., J.A.J., R.O., M.W.H., M.K., H.J., G.G.I., T.W., R.J., M.R., G.N., P.E., W.F.N., X.M.,
J.M.A., L.R., N.L.R., B.M.S., R.H.S., J.B.H., and K.L.M.S. assisted in the collection and characterization of the
Sjögren’s syndrome cases and healthy controls. K.M.K, A.J.A., and P.M.G. performed the genotyping. C.J.L., H.L.,
I.A., and J.A.I. performed all analyses and imputation under the guidance of C.G.M. and K.L.M.S. M.G.D. and
J.D.W performed the enrichment analysis. C.J.L., H.L., I.A., J.A.I., J.A.K., C.G.M., and K.L.S. prepared the
manuscript, and all authors approved the final draft.
Data access.
URLs.
HLA Genotype Imputation with Attribute Bagging http://cran.r-project.org/web/packages/HIBAG/
R Bioconductor suite http://www.R-project.org
Prism 6 http://www.graphpad.com/scientific-software/prism/
GenomeRunner http://sourceforge.net/projects/genomerunner
Genomatix Pathway System http://www.genomatix.de
Lessard et al. Page 14
Nat Genet. Author manuscript; available in PMC 2014 May 01.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sAccession Numbers: Genes and Blood Clotting Study dataset(s) obtained through dbGaP: phs000304.v1.p1
GWAS of Ischemic Stroke dataset(s) obtained through dbGaP: phs000292.v1.p1
CIDR:NGRC Parkinson’s disease study dataset(s) obtained through dbGaP: phs000196.v2.p1
High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes Investigation dataset(s)
obtained through dbGaP: phs000187.v1.p1
Competing Financial Interests: The authors declare no competing financial interests.
Acknowledgments
We are grateful to all the individuals with Sjögren’s syndrome and those serving as healthy controls who
participated in this study. We would like to thank the following individuals for their help in the collection and
ascertainment of the samples used in this study: Erin Rothrock, Judy Harris, Sharon Johnson, Sara Cioli, Nicole
Weber, Dominique Williams, Wes Daniels, Cherilyn Pritchett-Frazee, Kylia Crouch, Laura Battiest, Justin
Rodgers, James Robertson, Thuan Nguyen, Amanda Crosbie, Ellen James, Carolyn Meyer, Amber McElroy, Eshrat
Emamian, Julie Ermer, Kristine Rohlf, Joanlise Leon, Anita Petersen, Danielle Hartle, Jill Novizke, Ward Ortman,
Carl Espy, Beth Cobb, Gudlaug Kristjansdottir, Marianne Eidsheim and Joelle Benessiano Centre de Ressources
Biologiques, Hôpital Bichat, Paris, France. We would also like to thank Stuart Glenn and Jared Ning for their
ongoing assistance in developing and maintaining the computational infrastructure used to perform this study. We
would like to thank the following funding agencies for their support: This publication was made possible by grants
P50 AR0608040 (K.L.S., C.J.L., R.H.S., and A.D.F.), 5R01 DE015223 (K.L.S. and J.B.H.), 5RC2 AR058959
(P.M.G.), 5P01 AR049084-10 (J.B.H), 5P30 AR053483 (J.A.J. and J.M.G.), 5U19 AI082714 (K.L.S., J.A.J., and
C.J.L.), 1R01 DE018209-02 (K.L.S and J.B.H.), 5R01 DE018209 (K.L.S.), 8P20 GM103456 (P.M.G., C.J.L.,
J.D.W, and I.A.), P20 GM103636 (M.G.D. and J.D.W.), 5R37 AI024717-25 (J.B.H), 5P01 AI083194-03 (K.L.S.
and J.B.H.), 7S10 RR027190-02 (J.B.H.), 1U01 AI101934 (J.A.J. and J.M.G.), 1RC1 AR058554 (J.A.J. and
J.M.G.), and 5P30 GM103510 (J.A.J. AND J.M.G.) from the NIH. The contents are the sole responsibility of the
authors and do not necessarily represent the official views of the NIH. Additional funding was obtained from
Intramural Research Program of the National Institute of Dental and Craniofacial Research (G.G.I.), US
Department of Veterans Affairs IMMA 9 (J.B.H.), USA Department of Defense PR094002 (J.B.H), American
College of Rheumatology Research and Education Foundation/Abbott Health Professional Graduate Student
Preceptorship Award 2009 (C.J.L. and K.L.S.), Oklahoma Medical Research Foundation (C.J.L. and K.L.S.),
Sjögren’s Syndrome Foundation (K.L.S.), Phileona Foundation (K.L.S.), French ministry of health: PHRC N°2006-
AOM06133 and French ministry of research: ANR-2010-BLAN-1133 (X.M. and C.M.R.), The Strategic Research
Program at Helse Bergen, Western Norway Regional Health Authority (L.G.G., J.G.B., and R.J.), The Broegelmann
Foundation (J.G.B. and R.J.), Norwegian Foundation for Health and Rehabilitation (E.H.), KFO 250 TP03, WI
1031/6-1 (T.W.), KFO 250, Z1 (T.W.), Medical Research Council, UK G0800629 (W.F.N. and S.B.),
Northumberland, Tyne & Wear CLRN (W.F.N.), The Swedish Research Council (M.W.H. and L.R.), The King
Gustaf the V-th 80-year Foundation (M.W.H.), Knut and Alice Wallenberg Foundation (L.R.), and The Swedish
Rheumatism Association (M.W.H., G.N., L.R., and P.E.). This study made use of genotypes available through
dbGAP, with acknowledgment provided in the supplement.
References
1. Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the
United States. Part I. Arthritis Rheum. 2008; 58:15–25. [PubMed: 18163481]
2. Pillemer SR, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of
Olmsted County, Minnesota. Mayo Clin Proc. 2001; 76:593–9. [PubMed: 11393497]
3. Plesivcnik Novljan M, et al. Incidence of primary Sjogren’s syndrome in Slovenia. Ann Rheum Dis.
2004; 63:874–6. [PubMed: 15194588]
4. Jonsson R, et al. The complexity of Sjogren’s syndrome: novel aspects on pathogenesis. Immunol
Lett. 2011; 141:1–9. [PubMed: 21777618]
5. Vitali C, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European
criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61:554–8.
[PubMed: 12006334]
6. Thanou-Stavraki A, James JA. Primary Sjogren’s syndrome: current and prospective therapies.
Semin Arthritis Rheum. 2008; 37:273–92. [PubMed: 17714766]
7. Cobb BL, Lessard CJ, Harley JB, Moser KL. Genes and Sjogren’s syndrome. Rheum Dis Clin North
Am. 2008; 34:847–68. vii. [PubMed: 18984408]
Lessard et al. Page 15
Nat Genet. Author manuscript; available in PMC 2014 May 01.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s8. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor
salivary glands clearly distinguishes primary Sjogren’s syndrome patients from healthy control
subjects. Arthritis Rheum. 2005; 52:1534–44. [PubMed: 15880807]
9. Emamian ES, et al. Peripheral blood gene expression profiling in Sjogren’s syndrome. Genes
Immun. 2009; 10:285–96. [PubMed: 19404300]
10. Ice JA, et al. Genetics of Sjogren’s syndrome in the genome-wide association era. J Autoimmun.
2012; 39:57–63. [PubMed: 22289719]
11. Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjogren’s syndrome
susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012; 11:281–7. [PubMed:
22001416]
12. Korman BD, et al. Variant form of STAT4 is associated with primary Sjogren’s syndrome. Genes
Immun. 2008; 9:267–70. [PubMed: 18273036]
13. Miceli-Richard C, et al. Association of an IRF5 gene functional polymorphism with Sjogren’s
syndrome. Arthritis Rheum. 2007; 56:3989–94. [PubMed: 18050197]
14. Nordmark G, et al. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants
with primary Sjogren’s syndrome. Genes Immun. 2011; 12:100–9. [PubMed: 20861858]
15. Nordmark G, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary
Sjogren’s syndrome. Genes Immun. 2009; 10:68–76. [PubMed: 19092842]
16. Kang HI, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients
with primary Sjogren’s syndrome. J Immunol. 1993; 150:3615–23. [PubMed: 8468491]
17. A user’s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 2011; 9:e1001046.
[PubMed: 21526222]
18. Rossin EJ, et al. Proteins encoded in genomic regions associated with immune-mediated disease
physically interact and suggest underlying biology. PLoS Genet. 2011; 7:e1001273. [PubMed:
21249183]
19. Frisch M, Klocke B, Haltmeier M, Frech K. LitInspector: literature and signal transduction
pathway mining in PubMed abstracts. Nucleic Acids Res. 2009; 37:W135–40. [PubMed:
19417065]
20. Nekrep N, et al. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte
syndrome. Nat Immunol. 2002; 3:1075–81. [PubMed: 12368908]
21. Meissner TB, et al. NLRC5 cooperates with the RFX transcription factor complex to induce MHC
class I gene expression. J Immunol. 2012; 188:4951–8. [PubMed: 22490869]
22. Loiseau P, et al. HLA class I and class II are both associated with the genetic predisposition to
primary Sjogren syndrome. Hum Immunol. 2001; 62:725–31. [PubMed: 11423179]
23. Raychaudhuri S, et al. Five amino acids in three HLA proteins explain most of the association
between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012; 44:291–6. [PubMed:
22286218]
24. Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF
transcription factor family. Cancer Immunol Immunother. 2010; 59:489–510. [PubMed:
20049431]
25. Takaoka A, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like
receptors. Nature. 2005; 434:243–9. [PubMed: 15665823]
26. Sigurdsson S, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5
genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005; 76:528–37.
[PubMed: 15657875]
27. Sigurdsson S, et al. Association of a haplotype in the promoter region of the interferon regulatory
factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 2007; 56:2202–10. [PubMed: 17599733]
28. Stahl EA, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid
arthritis risk loci. Nat Genet. 2010; 42:508–14. [PubMed: 20453842]
29. Dideberg V, et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5)
gene confers risk of inflammatory bowel diseases. Hum Mol Genet. 2007; 16:3008–16. [PubMed:
17881657]
Lessard et al. Page 16
Nat Genet. Author manuscript; available in PMC 2014 May 01.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s30. Liu X, et al. Genome-wide meta-analyses identify three loci associated with primary biliary
cirrhosis. Nat Genet. 2010; 42:658–60. [PubMed: 20639880]
31. Dieude P, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic
sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 2009; 60:225–33. [PubMed:
19116937]
32. Radstake TR, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a
new susceptibility locus. Nat Genet. 2010; 42:426–9. [PubMed: 20383147]
33. Harley JB, et al. Genome-wide association scan in women with systemic lupus erythematosus
identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;
40:204–10. [PubMed: 18204446]
34. Graham RR, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and
protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 2007; 104:6758–63. [PubMed:
17412832]
35. Miceli-Richard C, et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a
strong risk factor for primary Sjogren’s syndrome. Arthritis Rheum. 2009; 60:1991–7. [PubMed:
19565491]
36. Sigurdsson S, et al. Comprehensive evaluation of the genetic variants of interferon regulatory
factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus
erythematosus. Hum Mol Genet. 2008; 17:872–81. [PubMed: 18063667]
37. Dawidowicz K, et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid
arthritis and influences its erosive phenotype. Ann Rheum Dis. 2011; 70:117–21. [PubMed:
20980283]
38. Kristjansdottir G, et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with
multiple sclerosis in three distinct populations. J Med Genet. 2008; 45:362–9. [PubMed:
18285424]
39. Kaplan MH. STAT4: a critical regulator of inflammation in vivo. Immunol Res. 2005; 31:231–42.
[PubMed: 15888914]
40. Remmers EF, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.
N Engl J Med. 2007; 357:977–86. [PubMed: 17804842]
41. Rueda B, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis
phenotype. Hum Mol Genet. 2009; 18:2071–7. [PubMed: 19286670]
42. Mells GF, et al. Genome-wide association study identifies 12 new susceptibility loci for primary
biliary cirrhosis. Nat Genet. 2011; 43:329–32. [PubMed: 21399635]
43. Gestermann N, et al. STAT4 is a confirmed genetic risk factor for Sjogren’s syndrome and could
be involved in type 1 interferon pathway signaling. Genes Immun. 2010; 11:432–8. [PubMed:
20535138]
44. Watford WT, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.
Immunological reviews. 2004; 202:139–56. [PubMed: 15546391]
45. Xu M, et al. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12,
IL-23, and IL-27. Clin Dev Immunol. 2010; 2010 [PubMed: 20885915]
46. Hirschfield GM, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2
variants. N Engl J Med. 2009; 360:2544–55. [PubMed: 19458352]
47. Hunt KA, et al. Newly identified genetic risk variants for celiac disease related to the immune
response. Nat Genet. 2008; 40:395–402. [PubMed: 18311140]
48. Lessard CJ, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for
systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet.
2012; 90:648–60. [PubMed: 22464253]
49. Gottenberg JE, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in
target organs of primary Sjogren’s syndrome. Proc Natl Acad Sci U S A. 2006; 103:2770–5.
[PubMed: 16477017]
50. Perez P, et al. Gene expression and chromosomal location for susceptibility to Sjogren’s syndrome.
J Autoimmun. 2009; 33:99–108. [PubMed: 19523788]
51. Cornall RJ, Goodnow CC. B cell antigen receptor signalling in the balance of tolerance and
immunity. Novartis Found Symp. 1998; 215:21–30. discussion 30-40. [PubMed: 9760569]
Lessard et al. Page 17
Nat Genet. Author manuscript; available in PMC 2014 May 01.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s52. Nemazee D, Weigert M. Revising B cell receptors. J Exp Med. 2000; 191:1813–7. [PubMed:
10839798]
53. Hom G, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-
ITGAX. N Engl J Med. 2008; 358:900–9. [PubMed: 18204098]
54. Simpfendorfer KR, et al. The autoimmunity-associated BLK haplotype exhibits cis-regulatory
effects on mRNA and protein expression that are prominently observed in B cells early in
development. Hum Mol Genet. 2012; 21:3918–25. [PubMed: 22678060]
55. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple
sclerosis. Nature. 2011; 476:214–9. [PubMed: 21833088]
56. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren’s syndrome: indications for disturbed selection
and differentiation in ectopic lymphoid tissue. Arthritis Res Ther. 2007; 9:218. [PubMed:
17697366]
57. Ma CS, et al. Early commitment of naive human CD4(+) T cells to the T follicular helper (T(FH))
cell lineage is induced by IL-12. Immunol Cell Biol. 2009; 87:590–600. [PubMed: 19721453]
58. Adrianto I, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus
erythematosus. Nat Genet. 2011; 43:253–8. [PubMed: 21336280]
59. Uddin M, Sturge M, Rahman P, Woods MO. Autosome-wide copy number variation association
analysis for rheumatoid arthritis using the WTCCC high-density SNP genotype data. J Rheumatol.
2011; 38:797–801. [PubMed: 21362769]
60. Allanore Y, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci
for systemic sclerosis. PLoS Genet. 2011; 7:e1002091. [PubMed: 21750679]
61. Nair RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB
pathways. Nat Genet. 2009; 41:199–204. [PubMed: 19169254]
62. Adrianto I, et al. Two independent functional risk haplotypes in TNIP1 are associated with
systemic lupus erythematosus. Arthritis Rheum. 2012
63. Gateva V, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1
and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009; 41:1228–33. [PubMed:
19838195]
64. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet. 2007; 81:559–75. [PubMed: 17701901]
65. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011; 13:101.
[PubMed: 21345260]
66. Price AL, et al. Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet. 2006; 38:904–9. [PubMed: 16862161]
67. McKeigue PM, Carpenter JR, Parra EJ, Shriver MD. Estimation of admixture and detection of
linkage in admixed populations by a Bayesian approach: application to African-American
populations. Ann Hum Genet. 2000; 64:171–86. [PubMed: 11246470]
68. Halder I, Shriver M, Thomas M, Fernandez JR, Frudakis T. A panel of ancestry informative
markers for estimating individual biogeographical ancestry and admixture from four continents:
utility and applications. Hum Mutat. 2008; 29:648–58. [PubMed: 18286470]
69. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
association scans. Bioinformatics. 2010; 26:2190–1. [PubMed: 20616382]
70. Cochran WG. The Combination of Estimates from Different Experiments. Biometrics. 1954;
10:101–29.
71. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj.
2003; 327:557–60. [PubMed: 12958120]
72. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype
maps. Bioinformatics. 2005; 21:263–5. [PubMed: 15297300]
73. Pruim RJ, et al. LocusZoom: regional visualization of genome-wide association scan results.
Bioinformatics. 2010; 26:2336–7. [PubMed: 20634204]
74. Frazer KA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature.
2007; 449:851–61. [PubMed: 17943122]
Lessard et al. Page 18
Nat Genet. Author manuscript; available in PMC 2014 May 01.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s75. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the
next generation of genome-wide association studies. PLoS Genet. 2009; 5:e1000529. [PubMed:
19543373]
76. Via M, Gignoux C, Burchard EG. The 1000 Genomes Project: new opportunities for research and
social challenges. Genome Med. 2010; 2:3. [PubMed: 20193048]
77. Zheng X, et al. HIBAG-HLA genotype imputation with attribute bagging. Pharmacogenomics J.
2013
78. Barbosa-Morais NL, et al. A re-annotation pipeline for Illumina BeadArrays: improving the
interpretation of gene expression data. Nucleic Acids Res. 2010; 38:e17. [PubMed: 19923232]
79. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array
probe level data. Biostatistics. 2003; 4:249–64. [PubMed: 12925520]
80. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using
empirical Bayes methods. Biostatistics. 2007; 8:118–27. [PubMed: 16632515]
81. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics.
2012; 28:1353–8. [PubMed: 22492648]
82. Dozmorov MG, Cara LR, Giles CB, Wren JD. GenomeRunner: Automating genome exploration.
Bioinformatics. 2011
83. Fujita PA, et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 2011;
39:D876–82. [PubMed: 20959295]
84. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features.
Bioinformatics. 2010; 26:841–2. [PubMed: 20110278]
Lessard et al. Page 19
Nat Genet. Author manuscript; available in PMC 2014 May 01.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sFigure 1.
Summary of genome-wide association results for 27,501 variants overlapping between DS1
and DS2 after imputation and meta-analysis. The −log10(P) for each variant is plotted
according to chromosome and base pair position. A total of seven loci (in red font) exceeded
the GWS of Pmeta < 5×10−8 (red dashed line). Suggestive threshold (Pmeta < 5×10−5) is
indicated by a blue dashed line.
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sFigure 2.
Zoomed in plots of the meta-analysis results for the seven regions with Pmeta<5×10−8. The
HLA region (a) from Mb 28.4 to Mb 33.4 is shown for variants with Pmeta<5×10−8 only.
Strong linkage disequilibrium (LD) was observed with variants extending from Class I
through Class II (pairwise LD with rs115575857 is given in blue). A second independent
effect was identified in Class II peaking at rs116232857 (pairwise LD is depicted in red).
The red insert on the left shows a further zoomed in view of the top associated variants in
the Class II region. (b) The area of association surrounding IRF5 is shown, including the
pairwise LD with the top overall variant, rs3757387, in blue. Pairwise LD with the top SNP,
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srs17339836, in the second effect is shown in red. STAT4 (c), IL12A (d), BLK (e), CXCR5 (f)
and TNIP1 (g) regions are also provided and include pairwise LD with the top listed variant
shown in blue. The black dashed lines represent Pmeta = 5×10−8.
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sFigure 3.
Identification of cis-eQTL in Sjögren’s syndrome-associated regions. Sjögren’s syndrome-
associated variants in the HLA region within 100bp of RFX5 binding sites were evaluated
for cis-eQTL with the expression of HLA genes in 222 European subjects. The top cis-eQTL
in HLA-DRB6 (a), HLA-C (b), HLA-DPB1 (c), HLA-DQA1 (d), and HLA-A (e) are shown in
the figure. We also identified cis-eQTL for top Sjögren’s syndrome-associated variants in
IL12A (f), FAM167A-BLK (g, h), and TNIP1 (i). The risk genotype of each eQTL variant is
plotted on the right side of each figure. Data are shown using box-and-whisker plots, in
which distribution of the expression values are highlighted (median, upper quantile, lower
quantile, maximum, and minimum). Each eQTL was evaluated using both a linear model
and Analysis of Variance (ANOVA) model. Panel b only had one subject with the TT
genotype; thus, we performed a t-test rather than an ANOVA to compare the TC to the CC
genotype.
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